IDDI at the 4th Annual Next Gen Immuno-Oncology Virtual Congress

June 28, 2021

IDDI presenting and meeting at the 4th US Annual Next Gen Immuno-Oncology Virtual Congress 

The Congress addresses the challenges and future directions in Immuno-oncology research.

  • On June 28, 13:15 – 13:45 (EST Time): Tomasz Burzykowski (PhD), Vice President, Research, IDDI will run a webinar on “EVALUATING TREATMENT EFFECT IN CLINICAL TRIALS IN IMMUNO-ONCOLOGY”
    In this session Prof. Burzykowski will discuss about the treatment effects on survival-type endpoints in randomized clinical trials (RCTs) in oncology that have been traditionally evaluated by using the proportional-hazard (PH) model. Also, observation on treatment effects incompatible with the PH assumption (like, for instance, delayed effects) in immuno-oncology (IO) will also be presented together with the statistical methods to best describe and test for treatment effects in RCTs in IO. A live Q&A session will be included for further discussion on the topic. 

  • IDDI Experts will be available to discuss your challenges and see how we can help you achieve your goals faster!

    SCHEDULE A MEETING today by contacting Vicky Martin, IDDI’s Senior Director of Business Development US at or Robert Whitaker, IDDI Director, Business Development, West Coast USA at

More information on the Congress’s Agenda and Registration can be found here.  

Next Generation Immuno-Oncology